Neurotech International Ltd Sustainability Reports

Neurotech International Limited is a clinical-stage biopharmaceutical development company focused on pediatric neurological disorders. The company conducts clinical trials and research to develop broad-spectrum oral cannabinoid drug therapies, such as its lead candidate NTI164.

Sector: Manufacturing

Country: Australia

Exchange: Australian Securities Exchange

FIGI: BBG00DSXRN80

11 reports from 2016 to 2026

• Neurotech International Ltd 2026 Annual Report
• Neurotech International Ltd 2024 Appendix 4E Preliminary Final Report
• Neurotech International Ltd 2024 Environmental Social Governance Disclosure Report
• Neurotech International Ltd 2023 Annual Report
• Neurotech International Ltd 2022 Annual Report